Previous Article | Next Article ![]()
J Virol, August 1998, p. 6796-6804, Vol. 72, No. 8
INSERM U372,
Received 17 September 1997/Accepted 27 April 1998
We previously reported that infection of goats with caprine
arthritis encephalitis virus (CAEV) tat
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Priming with tat-Deleted Caprine Arthritis
Encephalitis Virus (CAEV) Proviral DNA or Live Virus Protects Goats
from Challenge with Pathogenic CAEV

proviral DNA or
virus results in persistent infection, since the animals seroconverted and direct virus isolation from cultures of blood-derived macrophages was positive. In this study we wanted to determine whether goats injected with CAEV tat
proviral DNA or virus were
protected against challenge with the pathogenic homologous virus and to
investigate whether CAEV tat
was still pathogenic. All
animals injected with CAEV tat
became infected as
indicated by seroconversion and virus isolation. Challenge at 8 or 9 months postinfection demonstrated protection in four of four animals
injected with CAEV tat
but did not in three of three
mock-inoculated challenged goats. Challenge virus was undetectable in
the blood macrophages of protected animals during a period of 6 or 10 months postchallenge. In two of four protected animals, however, we
were able to detect the challenge wild-type virus by reverse
transcriptase PCR on RNA directly extracted from synovial membrane
cells surrounding the inoculation site. This result suggests that
protection was achieved without complete sterilizing immunity. Animals
injected with CAEV tat
and mock challenged developed
inflammatory lesions in the joints, although these lesions were not as
severe as those in CAEV wild-type-injected goats. These results confirm
the dispensable role of Tat in CAEV replication in vivo for the
establishment of infection and pathogenesis and demonstrate in another
lentivirus infection model the efficacy of live attenuated viruses to
induce resistance to superinfection.
*
Corresponding author. Mailing address: INSERM U372,
BP178, 13276 Marseille cedex 09, France. Phone: (33) 4 91 82 75 82. Fax: (33) 4 91 82 60 61. E-mail:
msuzan{at}inserm-U372.univ-mrs.fr.
Present address: Department of Microbiology, School of Medicine,
University of Washington, Seattle, WA 98195-7740.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|